Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 201

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 201
---
 in respect of those employees. The Company has made
all of the required payments as of December 31, 2024.

The fund is
made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination.

The severance
pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been
irrevocably transferred to the severance funds.

Severance expenses
for the years ended December 31, 2024 amounted to $16.

| k. | Income taxes: |

The Company
accounts for income taxes in accordance with ASC No. 740, “Income Taxes”, (“ASC 740”) which prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse.

The Company
provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024
a full valuation allowance was provided by the Company.

ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position
taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than
not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals
or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized
upon ultimate settlement. As of December 31, 2024 no liability for unrecognized tax benefits was recorded as a result of the implementation
of ASC 740

<div align='center'>F-12</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (Cont.)

| l. | Concentrations of credit risk: |

Financial instruments
that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. Cash and cash
equivalents are invested in major banks in Israel.

Management
believes that the financial institutions that hold the Company’s investments are financially sound and,